High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

Author(s):
Thielen, N.; Holt, B. van der; Verhoef, G.E.G.; Ammerlaan, R.A.H.M.; Sonneveld, P.; Janssen, J.J.W.M.; Deenik, W.; Falkenburg, J.H.F.; Kersten, M.J.; Sinnige, H.A.M.; Schipperus, M.; Schattenberg, A.; Kooy, R.V.; Smit, W.M.; Chu, I.W.T.; Valk, P.J.M.; Ossenkoppele, G.J.; Cornelissen, J.J.
Published
2013
Publication type
Article / Letter to editor
Chronic myeloid leukemiaImatinibCytarabineMajor molecular response
Date issued
2013-08-31
Language
English
Is part of
Annals of Hematology (2013), Vol. 92, no. 8, p. 1049-1056
hdl
1887/104460
doi
10.1007/s00277-013-1730-4